Notably, treatment with H. rhamnoides L. yielded a significant reduction in methylation of the PITX2, RASSF1, PTEN, and TIMP3 promoters, except ATM. These findings, supported by other preclinical and clinical BC studies, underscore the epigenetic-modulating potential of plant-derived bioactive compounds. The gene discussed is RASSF1; the disease is breast cancer.